ArticleJournal of clinical laboratory analysis2026
Development and Analytical Validation of a Smartphone-Based Quantitative Lateral Flow Immunoassay for Serum Cystatin-C.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCystatin-C is an important renal function biomarker, but conventional quantification requires centralized laboratory analyzers, limiting timely testing in primary care and resource-limited settings.
methodsWe developed and validated a quantitative smartphone-based lateral flow immunoassay (SP-LFIA) comprising a colorimetric strip, a Redmi Note 12R smartphone, a fixed-geometry macro-lens module with integrated LED illumination, and an Android application. The application directly converted background-corrected test/control-line (T/C) ratios into concentrations using a batch-specific third-order polynomial calibration model. Analytical validation followed relevant Clinical and Laboratory Standards Institute guidelines.
resultsThe assay showed a quantitative range of 0.32-8.00 mg/L and a limit of detection of 0.15 mg/L. Intra- and inter-assay coefficients of variation were below 10%. No significant interference was observed from bilirubin, triglycerides, hemoglobin, rheumatoid factor, gentamicin sulfate, norvancomycin hydrochloride, or cisplatin at the tested concentrations. Accelerated testing supported strip performance after storage at 50°C for 28 days. In 120 clinical serum samples, SP-LFIA agreed closely with the commercial particle-enhanced turbidimetric immunoassay reference method (R
conclusionThe smartphone-based LFIA provides a reliable, rapid, low-cost, and practical approach to quantitative Cystatin-C testing in point-of-care settings where serum preparation is available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.